The content on this website is intended solely for veterinarians and other animal health professionals.
By using this website, you confirm that the above applies to you.
Intervacc Announces Submission of Responses to EMA Day 120 Questions
Stockholm, January 12, 2021 – Intervacc AB (publ) announces that the responses to the Day 120 questions regarding the Company’s Marketing Authorization Application (MAA) for Strangvac® has been submitted today to the European Medicines Agency (EMA). Intervacc is...Intervacc appoints Emma Hartman as Global Product Manager for Strangvac
Stockholm, November 25, 2020 – The animal health group Intervacc AB (publ) has appointed Emma Hartman in the role of global product manager for Strangvac, a vaccine that is expected to become a game-changer in the fight against the global equine disease...Interim report January – September 2020
The period in summary Third quarter July 1 – September 30, 2020 Our marketing authorization application for Strangvac was submitted to the European Medicines Agency, EMA, at the end of February. During the third quarter, we have strengthened the dossier in the areas...Intervacc has carried out a directed issue of approximately 6.5 million shares, raising gross proceeds of approximately SEK 147 million
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND, UNITED STATES OF AMERICA OR ANY OTHER JURISDICTION IN WHICH THE PUBLICATION,...Intervacc intends to carry out a directed share issue
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE , IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND, UNITED STATES OF AMERICA OR ANY OTHER JURISDICTION IN WHICH THE PUBLICATION,...Nyhetstjänster
